Emerging retatrutide, a dual -action drug targeting equally GLP-1 and GIP receptors, is sparking considerable excitement within the medical community. Initial clinical research have shown impressive losses in body mass and advancements in health markers for patients with obesity . Researchers believe this unique approach may mark a major advance… Read More